These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 10866659)

  • 1. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene.
    Fredericks WJ; Ayyanathan K; Herlyn M; Friedman JR; Rauscher FJ
    Mol Cell Biol; 2000 Jul; 20(14):5019-31. PubMed ID: 10866659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene.
    Ayyanathan K; Fredericks WJ; Berking C; Herlyn M; Balakrishnan C; Gunther E; Rauscher FJ
    Cancer Res; 2000 Oct; 60(20):5803-14. PubMed ID: 11059777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
    Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
    Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulating the neoplastic phenotype using engineered transcriptional repressors.
    Fredericks WJ; Ayyanathan K; Rauscher FJ
    Cancer Lett; 2001 Jan; 162 Suppl():S23-S32. PubMed ID: 11164187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
    Bennicelli JL; Fredericks WJ; Wilson RB; Rauscher FJ; Barr FG
    Oncogene; 1995 Jul; 11(1):119-30. PubMed ID: 7624119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
    Barr FG
    Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A genetic analysis of PAX3-FKHR, the oncogene of alveolar rhabdomyosarcoma.
    Kempf BE; Vogt PK
    Cell Growth Differ; 1999 Dec; 10(12):813-8. PubMed ID: 10616906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.
    Sublett JE; Jeon IS; Shapiro DN
    Oncogene; 1995 Aug; 11(3):545-52. PubMed ID: 7630639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.
    Bennicelli JL; Edwards RH; Barr FG
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5455-9. PubMed ID: 8643596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.
    Hu Q; Yuan Y; Wang C
    PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
    Armoni M; Quon MJ; Maor G; Avigad S; Shapiro DN; Harel C; Esposito D; Goshen Y; Yaniv I; Karnieli E
    J Clin Endocrinol Metab; 2002 Nov; 87(11):5312-24. PubMed ID: 12414908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pax3-FKHR oncoprotein is unresponsive to the Pax3-associated repressor hDaxx.
    Hollenbach AD; Sublett JE; McPherson CJ; Grosveld G
    EMBO J; 1999 Jul; 18(13):3702-11. PubMed ID: 10393185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein.
    Xia SJ; Barr FG
    Oncogene; 2004 Sep; 23(41):6864-71. PubMed ID: 15286710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture.
    Scheidler S; Fredericks WJ; Rauscher FJ; Barr FG; Vogt PK
    Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9805-9. PubMed ID: 8790412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
    Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
    Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein.
    Xia SJ; Rajput P; Strzelecki DM; Barr FG
    Lab Invest; 2007 Apr; 87(4):318-25. PubMed ID: 17297479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma.
    Bennicelli JL; Advani S; Schäfer BW; Barr FG
    Oncogene; 1999 Jul; 18(30):4348-56. PubMed ID: 10439042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional regulation of IGF-I receptor gene expression by the PAX3-FKHR oncoprotein.
    Ayalon D; Glaser T; Werner H
    Growth Horm IGF Res; 2001 Oct; 11(5):289-97. PubMed ID: 11735247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain.
    Lam PY; Sublett JE; Hollenbach AD; Roussel MF
    Mol Cell Biol; 1999 Jan; 19(1):594-601. PubMed ID: 9858583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions.
    Collins MH; Zhao H; Womer RB; Barr FG
    Med Pediatr Oncol; 2001 Aug; 37(2):83-9. PubMed ID: 11496344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.